To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
IL1RAP Expression in Human Atherosclerosis: A Target of Novel Antibodies to Reduce Vascular Inflammation and Adhesion
Örebro University, School of Medical Sciences. Cardiovascular Research Centre, Faculty of Medicine and Health Örebro University Örebro Sweden.ORCID iD: 0000-0002-2732-158x
Örebro University, School of Medical Sciences. Cardiovascular Research Centre, Faculty of Medicine and Health Örebro University Örebro Sweden; Department of Clinical Research Laboratory, School of Medical Sciences, Faculty of Medicine and Health Örebro University Örebro Sweden.ORCID iD: 0000-0002-7498-7157
Örebro University, School of Medical Sciences. Cardiovascular Research Centre, Faculty of Medicine and Health Örebro University Örebro Sweden.ORCID iD: 0000-0002-4589-6440
Cardiovascular Research Centre, Faculty of Medicine and Health Örebro University Örebro Sweden; School of Medical Sciences, Faculty of Medicine and Health Örebro University Örebro Sweden.ORCID iD: 0000-0002-0927-4126
Show others and affiliations
2025 (English)In: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, E-ISSN 2047-9980, Vol. 14, no 10, article id e039557Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Blockade of IL1RAP (interleukin 1 receptor associated protein) was recently shown to reduce atherosclerosis in mice, but the effect on human vascular cells is largely unknown. Targeting the IL1RAP coreceptor represents a novel strategy to block the IL1RAP-dependent cytokines IL (interleukin)-1, IL-33, and IL-36. In the present study, we aimed to evaluate the role of novel antibodies targeting IL1RAP to reduce the effects of IL-1β, IL-33, or IL-36γ in human vascular cells.

METHODS: Expression of IL1RAP was observed in human atherosclerotic plaques by immunohistochemistry and microarray and in endothelial cells by flow cytometry. Endothelial cells were cultured with IL-1β, IL-33, or IL-36γ cytokines with or without IL1RAP antibodies and analyzed with Olink proteomics, ELISA, Western blot, and real-time quantitative polymerase chain reaction. The functional effect of IL1RAP antibodies on endothelial cells were analyzed with adhesion and permeability assays.

RESULTS: Olink proteomics showed inhibition of the inflammatory proteins LIF (leukemia inhibitory factor), OPG (osteoprotegerin), CCL4 (C-C motif chemokine ligand 4), and MCP-3 (monocyte chemoattractant protein 3) by IL1RAP-blockade in endothelial cells after IL-1β stimulation. In addition, the IL1RAP antibodies inhibited IL-1β, and IL-33 induced IL-6 and IL-8 secretion. Secretion of MCP-1 (monocyte chemoattractant protein 1) was induced by IL-1β, IL-33, and IL-36γ, and subsequently was inhibited by IL1RAP antibodies. Similar effects were found on mRNA expression level. Endothelial expression of the adhesion markers ICAM1, VCAM1, and SELE were significantly reduced by IL1RAP antibodies, and neutrophil adhesion to endothelial cells induced by IL-1β and IL-33 was reduced by IL1RAP blockade. In human atherosclerotic lesions, IL1RAP expression correlated with markers of inflammation like IL6, IL8, and MCP1.

CONCLUSIONS: IL1RAP-targeting antibodies can reduce the expression of inflammatory cytokines and markers of adhesion in endothelial cells, which may be of importance for future putative targeted treatments against cardiovascular disease.

Place, publisher, year, edition, pages
John Wiley & Sons, 2025. Vol. 14, no 10, article id e039557
Keywords [en]
HUVECs, IL‐1, IL‐33, IL‐36, endothelial cells
National Category
Cardiology and Cardiovascular Disease
Identifiers
URN: urn:nbn:se:oru:diva-121087DOI: 10.1161/JAHA.124.039557ISI: 001491258200001PubMedID: 40371594OAI: oai:DiVA.org:oru-121087DiVA, id: diva2:1958679
Funder
Knowledge Foundation, 20170191Knowledge Foundation, 20190088Knowledge Foundation, 20220083Örebro University, 2019‐06‐13Available from: 2025-05-16 Created: 2025-05-16 Last updated: 2025-05-27Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Lindkvist, MadeleneGöthlin Eremo, AnnaParamel Varghese, GeenaSirsjö, AllanFransén, Karin

Search in DiVA

By author/editor
Lindkvist, MadeleneGöthlin Eremo, AnnaParamel Varghese, GeenaAnisul Haque, SheikhSirsjö, AllanFransén, Karin
By organisation
School of Medical Sciences
In the same journal
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Cardiology and Cardiovascular Disease

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 190 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf